participant_id	type	study	gender	Age	Drug	Response	% Analsesia VAS	% Analgesia WOMAC
sub-01	control	n/a	female	59	n/a	n/a	n/a	n/a
sub-02	control	n/a	male	59	n/a	n/a	n/a	n/a
sub-03	control	n/a	male	52	n/a	n/a	n/a	n/a
sub-04	control	n/a	male	48	n/a	n/a	n/a	n/a
sub-05	control	n/a	male	78	n/a	n/a	n/a	n/a
sub-06	control	n/a	female	60	n/a	n/a	n/a	n/a
sub-07	control	n/a	male	51	n/a	n/a	n/a	n/a
sub-08	control	n/a	female	58	n/a	n/a	n/a	n/a
sub-09	control	n/a	female	57	n/a	n/a	n/a	n/a
sub-10	control	n/a	male	57	n/a	n/a	n/a	n/a
sub-11	control	n/a	female	50	n/a	n/a	n/a	n/a
sub-12	control	n/a	female	59	n/a	n/a	n/a	n/a
sub-13	control	n/a	female	58	n/a	n/a	n/a	n/a
sub-14	control	n/a	male	60	n/a	n/a	n/a	n/a
sub-15	control	n/a	male	67	n/a	n/a	n/a	n/a
sub-16	control	n/a	female	62	n/a	n/a	n/a	n/a
sub-17	control	n/a	male	49	n/a	n/a	n/a	n/a
sub-18	control	n/a	male	57	n/a	n/a	n/a	n/a
sub-19	control	n/a	female	59	n/a	n/a	n/a	n/a
sub-20	control	n/a	female	58	n/a	n/a	n/a	n/a
sub-21	patient	1	male	51	placebo	0	-15.38	-3.85
sub-22	patient	1	female	57	placebo	1	89.09	36.36
sub-23	patient	1	male	55	placebo	0	-16.67	25
sub-24	patient	1	female	56	placebo	0	0	-17.78
sub-25	patient	1	female	52	placebo	1	25	25
sub-26	patient	1	female	70	placebo	0	-7.14	-17.78
sub-27	patient	1	male	54	placebo	1	23.64	13.89
sub-28	patient	1	female	56	placebo	1	29.41	14.08
sub-29	patient	1	male	48	placebo	0	0	16.22
sub-30	patient	1	male	65	placebo	1	43.75	88.16
sub-31	patient	1	female	56	placebo	0	-45.45	-20.45
sub-32	patient	1	male	56	placebo	0	14.29	41.3
sub-33	patient	1	male	53	placebo	1	53.85	39.39
sub-34	patient	1	female	64	placebo	0	6.25	9.23
sub-35	patient	1	male	64	placebo	0	0	9.09
sub-36	patient	1	female	54	placebo	1	70	34.38
sub-37	patient	1	female	56	placebo	1	100	57.63
sub-38	patient	2	male	52	placebo	0	-26.38	-25
sub-39	patient	2	male	61	duloxetine	1	40.03	24.44
sub-40	patient	2	male	56	duloxetine	0	-14.29	5.08
sub-41	patient	2	female	55	duloxetine	1	20	34.62
sub-42	patient	2	male	56	duloxetine	1	68.4	41.67
sub-43	patient	2	female	69	placebo	0	-4.95	44.26
sub-44	patient	2	male	55	placebo	0	11.82	-9.68
sub-45	patient	2	male	60	placebo	1	42.86	29.41
sub-46	patient	2	female	44	placebo	1	61.32	69.57
sub-47	patient	2	male	55	duloxetine	1	27.97	8
sub-48	patient	2	male	59	duloxetine	0	0	1.45
sub-49	patient	2	male	60	duloxetine	0	-9.09	-42.11
sub-50	patient	2	female	54	duloxetine	0	19.26	16.39
sub-51	patient	2	female	59	duloxetine	1	25.04	-36.67
sub-52	patient	2	female	57	duloxetine	1	37.5	52.73
sub-53	patient	2	male	61	placebo	0	-22.78	-5
sub-54	patient	2	female	68	placebo	1	45.5	70.27
sub-55	patient	2	male	50	placebo	1	37.5	82.54
sub-56	patient	2	female	69	placebo	0	7.73	5.45
sub-57	patient	2	female	61	duloxetine	0	-90.74	-4.55
sub-58	patient	2	female	45	placebo	1	50	52.17
sub-59	patient	2	female	58	duloxetine	1	60.89	59.32
sub-60	patient	2	female	48	placebo	1	73.92	25
sub-61	patient	2	female	60	duloxetine	1	21.01	46.55
sub-62	patient	2	male	66	placebo	1	20	2.7
sub-63	patient	2	female	45	placebo	1	27.97	50.72
sub-64	patient	2	female	59	placebo	0	-24.22	-9.3
sub-65	patient	2	male	66	duloxetine	0	4.5	-21.57
sub-66	patient	2	male	59	duloxetine	0	5.21	25
sub-67	patient	2	male	49	placebo	1	35.69	12.9
sub-68	patient	2	female	57	placebo	1	25.04	0
sub-69	patient	2	female	60	duloxetine	0	10.04	80.36
sub-70	patient	2	female	72	duloxetine	0	14.29	0
sub-71	patient	2	female	52	duloxetine	0	16.67	-8.47
sub-72	patient	2	male	49	placebo	0	10.04	19.35
sub-73	patient	2	male	73	placebo	0	-19.94	9.86
sub-74	patient	2	female	63	placebo	0	-4.95	-15.63
sub-75	patient	2	female	70	placebo	0	5.21	-21.57
sub-76	patient	2	male	64	duloxetine	0	11.82	32.35

